Opportunity analysis of an antibody-cleaving enzyme in oncology & autoimmune diseases

Challenge: A biopharmaceutical company with a focus on immunomodulatory compounds was looking to expand the application of its lead product in oncology, specifically, by adapting the product to...
Learn More

Indication selection assessment for clinical stage oncology small molecule

Challenge: A venture capital firm was interested in an independent indication selection strategic assessment of a clinical stage small molecule oncology asset they had invested in, based on the...
Learn More

Opportunity mapping in myelofibrosis for phase II product

Challenge: An inflammation and oncology-focused biotech company was looking to expand the clinical footprint of one of its phase II products. Our client was discussing the potential positioning of...
Learn More

Due diligence on a reverse merger candidate with pipeline of IND-ready compounds

Challenge: A NASDAQ-listed biotech asked Alacrita to conduct a technical due diligence on a prospect reverse merger candidate. After screening numerous companies, our client identified a strong...
Learn More

Building Target Product Profiles and conducting rNPV valuations of lead assets

Challenge: A clinical stage company developing small molecules to treat fibrotic diseases engaged Alacrita to quantify the value potential of their lead asset in idiopathic pulmonary fibrosis (IPF),...
Learn More

Opportunity mapping & indication strategy for company developing exosome-based therapies

Challenge: A clinical stage stem-cell company with its own proprietary cell lines had developed technologies to enable production of exosomes at a commercially relevant scale. The company asked...
Learn More

Interim Chief Medical Officer support for an immuno-oncology biopharma company

Challenge: A European biopharma company focused on immuno-oncology therapeutics was developing small molecule and monoclonal antibody agents for three targets of high interest in the I/O field. The...
Learn More

EU payer research for novel mAb treatment for hidradenitis suppurativa

Challenge: A biotech company that had recently completed a late-stage clinical trial for its first-in-class mAb therapy for a chronic inflammatory skin disease wanted to test the use of a newly...
Learn More

Due diligence of first-in-class monoclonal antibody candidate drug

Challenge: A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to provide an...
Learn More

Pre-due diligence of two early-stage assets: a nano-ADC & a small molecule

Challenge: A pharma company sought Alacrita's support in providing high-level go/no-go pre-due diligence of two early-stage strategic investment opportunities. The company had so far been focused on...
Learn More

Strategic analysis of preclinical data for a lipid combination treatment

Challenge: A European biopharma company developing synthetic lipids required a critical appraisal of data generated by a University research group using natural lipids in oncology. It wished to...
Learn More

Pharmaceutical Regulatory Affairs Case Studies

Alacrita's regulatory affairs consultants provide support to biotech, pharmaceutical and medtech clients, as well as companies and investors conducting regulatory due diligence. Our regulatory team...
Learn More